The Challenge

The problem of aldehyde toxicity:

Across an expanse of serious diseases.


Free aldehydes are naturally occurring toxins. While nearly every organism has enzymes to catabolize aldehydes, in cases of inflammatory and other types of diseases, aldehydes overwhelm the metabolic system and lead to significant pathology.

At Aldeyra Therapeutics, our mission is to develop therapies to mitigate the effects of aldehyde toxicity. These therapies represent a novel approach to treat, prevent, or slow the progression of numerous rare and common autoimmune, inflammatory, neurological, cardiovascular and metabolic diseases.

Learn more about the widespread challenge of aldehyde toxicity


Our Novel Platform

Neutralizing the toxic effects of aldehydes:

Starting with a family of small-molecule traps.


Aldeyra has developed a proprietary family of aldehyde traps: new chemical entities that sequester and allow for the degradation of free aldehydes. Generally safe and well-tolerated in animal and human testing, these entities exhibit minimal pharmacology and have been shown to bind and trap free aldehydes more quickly than aldehydes can bind cellular constituents.

We believe this is the first concerted pharmaceutical effort to lower free aldehyde levels. The result is a novel platform of drug candidates with broad therapeutic potential across immune-mediated, inflammatory, orphan and other diseases.

Learn more about our novel platform


Development Status

The current state of our clinical trials:

Potential therapies for Sjögren-Larsson Syndrome and noninfectious anterior uveitis.

Our lead compound and most advanced product candidate, NS2, is now in two clinical trials for diseases mediated by aldehydes: Sjögren-Larsson Syndrome (SLS) and noninfectious anterior uveitis.

Learn more about our development status

Sjögren-Larsson Syndrome (SLS)

SLS is caused by genetic mutations in Fatty Aldehyde Dehydrogenase (FALDH) that lead to high fatty aldehyde levels, resulting in severe skin and neurological disease. There are an estimated 1000 patients in the US, but there is no FDA-approved therapy specifically for the disease. By trapping fatty aldehydes and replacing the missing catabolic function of FALDH, NS2 represents a potential therapeutic approach for SLS.

Noninfectious anterior uveitis

Noninfectious anterior uveitis is a severe inflammatory eye disease characterized in part by high aldehyde levels that may cause pain, photophobia, redness, loss of vision, and other ocular symptoms.* By trapping pro-inflammatory aldehydes, NS2 has the potential to mitigate inflammation in uveitis and other inflammatory diseases.

* Uveitis can be treated with corticosteroids, which can lead to cataracts, glaucoma, increased ocular infection rates, corneal ulceration, and other toxicities.


Leadership Team

Maximizing our internal capabilities:

From a research, development and strategic viewpoint.


Since 2012, Aldeyra has been guided by a leadership team with exceptional depth and breadth of expertise. This includes first-hand experience with the advancement of promising candidates from lab testing, to early and late-stage clinical trials, to the development of approved drugs. This knowledge, which extends to institutional financing and strategic business development, is augmented by a prominent board of directors with a formidable list of achievements and relevant expertise.

Learn more about our leadership team



We’re looking for a few exceptional people:

Who are ready to make a world of difference.


As our company grows and continues to evolve, we are always looking to enhance our clinical and corporate teams with the talents of gifted and driven individuals. If you’re excited by the prospect of being part of a revolutionary medical technology — and possess the knowledge and initiative to help energize our cause — we would be pleased to hear from you.

Learn more about careers at Aldeyra